liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
GAD65: a prospective vaccine for treating Type 1 diabetes?
Linköping University, Department of Clinical and Experimental Medicine, Division of Children's and Women's health. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center of Paediatrics and Gynaecology and Obstetrics, Department of Paediatrics in Linköping.
2017 (English)In: Expert Opinion on Biological Therapy, ISSN 1471-2598, E-ISSN 1744-7682, Vol. 17, no 8, 1033-1043 p.Article in journal (Refereed) Published
Abstract [en]

Introduction: In spite of modern techniques, the burden for patients with type 1 diabetes (T1D) will not disappear and T1D remains a life-threatening disease causing severe complications and increased mortality. We have to learn how to preserve residual insulin secretion or even increase beta cell regeneration. This would give a milder disease, simpler treatment and perhaps even cure. Thus, there are good reasons to try therapies that may preserve beta cell function.Areas covered: In this review the author reviews the literature and registered ongoing trials using GAD-alum put in relation to the high number of published different immune interventions.Expert opinion: GAD-alum treatment is safe, tolerable and easy for the patients and healthcare. It seems probable that treatment with GAD65-alum 20 mu g sc can preserve residual beta cell function in T1D, but efficacy needs to be improved. This may be achieved by the use of combination therapies and new approaches for administration.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD , 2017. Vol. 17, no 8, 1033-1043 p.
Keyword [en]
GAD65-alum; Type 1 diabetes; immune intervention; prevention; combination therapy; intra-lymphatic treatment; children
National Category
Immunology in the medical area
Identifiers
URN: urn:nbn:se:liu:diva-139662DOI: 10.1080/14712598.2017.1328495ISI: 000405478000012PubMedID: 28480759OAI: oai:DiVA.org:liu-139662DiVA: diva2:1133558
Note

Funding Agencies|Swedish Child Diabetes Foundation (Barndiabetesfonden); Juvenile Diabetes Research Foundation; Research Council of Southeast Sweden (FORSS); Diabetesfonden (Swedish Diabetes Association); Phase II/III GAD trials

Available from: 2017-08-16 Created: 2017-08-16 Last updated: 2017-08-16

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Ludvigsson, Johnny
By organisation
Division of Children's and Women's healthFaculty of Medicine and Health SciencesDepartment of Paediatrics in Linköping
In the same journal
Expert Opinion on Biological Therapy
Immunology in the medical area

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 35 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf